{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:59:40Z","timestamp":1764935980579,"version":"3.37.3"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the circulating micro-RNA-150 (miR-150) expression in patients with chronic myeloid leukemia (CML) in relation to imatinib response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sixty patients with CML and 20 age- and sex-matched control subjects were enrolled. Circulating miR-150 levels were assessed by quantitative real-time polymerase chain reaction on days 0, 14, and 90 of imatinib therapy for patients and once for control subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The baseline miR-150 expression was significantly lower in patients with CML than in control subjects with subsequent elevation at 14 and 90 days after the start of imatinib treatment. Early treatment response (ETR) at 90 days was the main study outcome. The miR-150 expression had a significantly higher level in patients with CML with ETR. On multivariate analysis, miR-150 on day 14 was significantly related to ETR in patients with CML with predictive efficacy (area under the curve\u2005=\u20050.838, 72.9% sensitivity, and 84.2% specificity).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found that miR-150 expression on day 14 of imatinib treatment is a useful early predictive candidate for imatinib response in patients with CML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmab040","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T11:39:56Z","timestamp":1617968396000},"page":"58-64","source":"Crossref","is-referenced-by-count":26,"title":["MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response"],"prefix":"10.1093","volume":"53","author":[{"given":"Eman M","family":"Habib","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Kafr El-Sheikh University , Kafr El-Sheikh , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahla A","family":"Nosiar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Kafr El-Sheikh University , Kafr El-Sheikh , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal A","family":"Eid","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Tanta University , Tanta , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atef M","family":"Taha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Tanta University , Tanta , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia E","family":"Sherief","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Kafr El-Sheikh University , Kafr El-Sheikh , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa E","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Kafr El-Sheikh University , Kafr El-Sheikh , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0621-4291","authenticated-orcid":false,"given":"Muhammad T","family":"Abdel Ghafar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Tanta University , Tanta , Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"6","key":"2023111812031922400_CIT0001","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia."},{"issue":"4","key":"2023111812031922400_CIT0002","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1389557518666181017124854","article-title":"Chronic myeloid leukemia: existing therapeutic options and strategies to overcome drug resistance","volume":"19","author":"Singh","year":"2019","journal-title":"Mini Rev Med Chem."},{"issue":"1","key":"2023111812031922400_CIT0003","first-page":"1","article-title":"Current perspectives for the treatment of chronic myeloid leukemia","volume":"49","author":"Alada\u011f","year":"2019","journal-title":"Turk J Med Sci."},{"issue":"10","key":"2023111812031922400_CIT0004","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41375-019-0562-1","article-title":"Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia."},{"key":"2023111812031922400_CIT0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3389\/fonc.2019.00833","article-title":"Monitoring chronic myeloid leukemia: how molecular tools may drive therapeutic approaches","volume":"9","author":"Izzo","year":"2019","journal-title":"Front Oncol."},{"issue":"1","key":"2023111812031922400_CIT0006","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia","volume":"15","author":"Yeh","year":"2016","journal-title":"Mol Cancer."},{"issue":"27","key":"2023111812031922400_CIT0007","doi-asserted-by":"crossref","first-page":"42683","DOI":"10.18632\/oncotarget.7977","article-title":"MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia","volume":"7","author":"Chakraborty","year":"2016","journal-title":"Oncotarget."},{"key":"2023111812031922400_CIT0008","doi-asserted-by":"crossref","first-page":"695754","DOI":"10.1155\/2013\/695754","article-title":"MicroRNAs as haematopoiesis regulators","volume":"2013","author":"Undi","year":"2013","journal-title":"Adv Hematol."},{"issue":"9","key":"2023111812031922400_CIT0009","doi-asserted-by":"crossref","first-page":"e2371","DOI":"10.1038\/cddis.2016.256","article-title":"miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways","volume":"7","author":"Fang","year":"2016","journal-title":"Cell Death Dis."},{"issue":"30","key":"2023111812031922400_CIT0010","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/onc.2013.346","article-title":"The role of miR-150 in normal and malignant hematopoiesis","volume":"33","author":"He","year":"2014","journal-title":"Oncogene."},{"key":"2023111812031922400_CIT0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","journal-title":"Mol Cancer."},{"issue":"1-2","key":"2023111812031922400_CIT0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-013-1958-2","article-title":"Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia","volume":"390","author":"Zhu","year":"2014","journal-title":"Mol Cell Biochem."},{"issue":"8","key":"2023111812031922400_CIT0013","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica."},{"issue":"2","key":"2023111812031922400_CIT0014","first-page":"159","article-title":"MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia","volume":"121","author":"Yurt","year":"2020","journal-title":"Bratisl Lek Listy."},{"issue":"20","key":"2023111812031922400_CIT0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"4","key":"2023111812031922400_CIT0016","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."},{"key":"2023111812031922400_CIT0017","first-page":"1108","article-title":"Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume-title":"J Natl Compr Canc Netw.","author":"Radich","year":"2018"},{"issue":"6","key":"2023111812031922400_CIT0018","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc."},{"key":"2023111812031922400_CIT0019","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol."},{"issue":"3","key":"2023111812031922400_CIT0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol."},{"issue":"9","key":"2023111812031922400_CIT0021","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia."},{"issue":"3","key":"2023111812031922400_CIT0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bjhh.2017.04.007","article-title":"Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia","volume":"39","author":"Vieira-Mion","year":"2017","journal-title":"Rev Bras Hematol Hemoter."},{"issue":"9","key":"2023111812031922400_CIT0023","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1080\/10428194.2017.1422860","article-title":"The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China","volume":"59","author":"Shao","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2023111812031922400_CIT0024","doi-asserted-by":"crossref","first-page":"150","DOI":"10.11622\/smedj.2016063","article-title":"The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country","volume":"58","author":"Bee","year":"2017","journal-title":"Singapore Med J."},{"issue":"7","key":"2023111812031922400_CIT0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-018-0093-4","article-title":"Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance","volume":"8","author":"Zhang","year":"2018","journal-title":"Blood Cancer J."},{"issue":"4","key":"2023111812031922400_CIT0026","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s11033-020-05334-5","article-title":"Role of serum metadherin mRNA expression in the diagnosis and prediction of survival in patients with colorectal cancer","volume":"47","author":"Abdel Ghafar","year":"2020","journal-title":"Mol Biol Rep."},{"key":"2023111812031922400_CIT0027","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.genrep.2020.100706","article-title":"Serum high-temperature-required protein A2: a potential biomarker for the diagnosis of breast cancer","volume":"20","author":"Abdel Ghafar","year":"2020","journal-title":"Gene Rep."},{"key":"2023111812031922400_CIT0028","first-page":"91","article-title":"Serum HOX transcript antisense RNA expression as a diagnostic marker for chronic myeloid leukemia","author":"Abdel Ghafar","year":"2019"},{"issue":"1","key":"2023111812031922400_CIT0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43046-019-0005-0","article-title":"Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival","volume":"31","author":"El-Guindy","year":"2019","journal-title":"J Egypt Natl Canc Inst."},{"issue":"3","key":"2023111812031922400_CIT0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1261\/rna.7240905","article-title":"Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes","volume":"11","author":"Baskerville","year":"2005","journal-title":"RNA."},{"issue":"9","key":"2023111812031922400_CIT0031","doi-asserted-by":"crossref","first-page":"e75815","DOI":"10.1371\/journal.pone.0075815","article-title":"MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors","volume":"8","author":"Morris","year":"2013","journal-title":"PLoS One."},{"issue":"2","key":"2023111812031922400_CIT0032","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.exphem.2009.11.004","article-title":"C\/EBPepsilon directs granulocytic-vs-monocytic lineage determination and confers chemotactic function via Hlx","volume":"38","author":"Halene","year":"2010","journal-title":"Exp Hematol."},{"issue":"9","key":"2023111812031922400_CIT0033","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2007-08-105072","article-title":"Requirement of c-Myb for p210(BCR\/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis","volume":"111","author":"Lidonnici","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2023111812031922400_CIT0034","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cell.2005.09.023","article-title":"A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C\/EBPalpha regulates human granulopoiesis","volume":"123","author":"Fazi","year":"2005","journal-title":"Cell."},{"issue":"11","key":"2023111812031922400_CIT0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/cbin.10157","article-title":"Design of polyethylene glycol-polyethylenimine nanocomplexes as non-viral carriers: mir-150 delivery to chronic myeloid leukemia cells","volume":"37","author":"Biray Avc\u0131","year":"2013","journal-title":"Cell Biol Int."},{"issue":"4","key":"2023111812031922400_CIT0036","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1541-7786.MCR-14-0422","article-title":"c-MYC generates repair errors via increased transcription of alternative-NHEJ factors, LIG3 and PARP1, in tyrosine kinase-activated leukemias","volume":"13","author":"Muvarak","year":"2015","journal-title":"Mol Cancer Res."},{"issue":"12","key":"2023111812031922400_CIT0037","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/1\/58\/53510743\/lmab040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/1\/58\/53510743\/lmab040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:03:56Z","timestamp":1700309036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/1\/58\/6341662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,5]]},"published-print":{"date-parts":[[2022,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab040","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"type":"print","value":"0007-5027"},{"type":"electronic","value":"1943-7730"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,5]]}}}